pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
341
stories
Jun 16, 26
How to launch a telehealth business in one day
endpoints
Jun 16, 26
How supplement use changed over decades
stat
Jun 15, 26
STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end
stat
Jun 12, 26
Sciwind has two Western partners for its obesity drug, but is open to more
endpoints
Jun 11, 26
STAT+: An obesity drug deep-dive, and peptides move mainstream
stat
Jun 11, 26
STAT+: Novartis doubles down on molecular glue strategy
stat
Jun 11, 26
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
stat
Jun 10, 26
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 9, 26
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
stat
Jun 8, 26
Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
stat
Jun 8, 26
#ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months
endpoints
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 8, 26
Opinion: American horses are obese, too
stat
Jun 7, 26
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
endpoints
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 6, 26
#ADA26: Pfizer's monthly shot shows effect on obesity, diabetes
endpoints
Jun 5, 26
#ADA26: Roche's incretin shot works in mid-stage trial in type 1 diabetes
endpoints
Jun 5, 26
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
stat
Jun 5, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jun 5, 26
Texas AG investigating energy drinks
stat
Jun 5, 26
STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
stat
Jun 4, 26
STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
stat
Jun 4, 26
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
stat
Jun 4, 26
STAT+: Utah Medical Board scolded for going rogue with AI criticism
stat
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
Jun 3, 26
What it will take for more employer GLP-1 coverage
endpoints
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
← prev
page 10 of 12
next →
